The Global D-Dimer Testing Market is anticipated to grow at a significant CAGR during the forecasted period. D-Dimer Testing helps in the identification of the fibrinolysis of a clot of the blood in the human blood samples and also helps in the identification of various diseases. As the prevalence of the COVID-19 pandemic, infection within the geriatric population is high in numbers and also rise in the numbers of a respiratory and/or cardiovascular complication (i.e. Venous thromboembolism (VTE)) among hospitalized patients. Recently, approximately 25% of the COVID-19 ICU hospitalized patients are receiving the anticoagulant treatment; as geriatric patients are showing signs of coagulation. The D-Dimer Testing got an attention owing to the shifting trend towards Next Generation of POC D-Dimer Testing; driving the D-Dimer Testing market growth.
Reduction in waiting time, minimization of patient hospitalization stays, faster diagnosis, and improvisation of patient experience has prompted to implement the POC solutions supported the market growth. According to the Centers for Disease Control and Prevention (CDC), approximately 900,000 people are impacted due to VTE every year, and 60,000-100,000 patients in the U.S. died due to the impact of VTE. The use of Aptamers has been found to be a cost-effective and long-term approach which reduces the use of the antibodies during D-Dimer Testing and also has stability, quicker to produce, and has longer shelf life than antibodies. Hence, Aptamers are another reason for market growth globally. Ayass Bioscience LLC is currently working on aptamers and its provision for the usage which has found to be useful in manual POC agglutination tests and homogeneous assays.
Rising - frequency of cardiovascular diseases, blood-related disorders such as platelet disorders, and blood cancers, increasing demand for next-generation coagulation testing methods, huge number of geriatric population across the globe, and availability of the investments for next-generation technologies have boosted the market growth.
In 2019, the laboratory testing method has been dominant in the market with approx. USD 525.2 million which is expected to be dominant during 2020-2027 due to the high adoption rate of the POC testing devices as well as qualitative and quantitative cross-linked fibrin degeneration items. Deep Vein Thrombosis has been dominant in the market with a 37.1% market share. The factors for the market growth within this segment are the growth of geriatric populaces, consumer awareness, and the increasing prevalence of diseases. Hospitals have been the dominant with the value of USD 180.4 mn (i.e. 36.3%) due to the factors such as a rise in the number of occurrences of blood-related disorders and higher prevalence & mortality rate because of deep vein thrombosis and pulmonary embolism in both developed & developing nations across the globe.
The adoption of strategic growth capabilities by the market players has led to the reinforcement of their product offerings and to have a competitive edge in the global D-Dimer Testing Market. Furthermore, the development of sensitive and automated hemostasis markers can give an opportunity for diversification of the market potential for the market players. For instance, in April 2019, Ortho Clinical Diagnostics, a U.S.-based company, launched its D-Dimer assay together with Diazyme Laboratories, Inc. This new assay is one among the newest product of MicroTip Partnership Assay Program of Ortho Clinical, which permit the corporate to supply high value, flexible, quick, and esoteric testing solutions. This product launch expanded the company’s expertise to supply innovative assay to its customers.